Stemline Therapeutics Inc (NASDAQ:STML)’s share price traded down 8.7% during mid-day trading on Wednesday . The stock traded as low as $13.55 and last traded at $13.71, 733,431 shares changed hands during trading. An increase of 22% from the average session volume of 601,572 shares. The stock had previously closed at $15.01.

Several equities research analysts have recently issued reports on the stock. Roth Capital reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Thursday, May 23rd. Cowen reiterated a “buy” rating on shares of Stemline Therapeutics in a research report on Sunday, August 4th. HC Wainwright set a $35.00 price objective on shares of Stemline Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 20th. Zacks Investment Research cut shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, Wedbush upgraded shares of Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a research report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Stemline Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.50.

The firm’s 50-day moving average is $14.29 and its two-hundred day moving average is $13.68. The company has a market cap of $659.84 million, a P/E ratio of -4.59 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.71 and a quick ratio of 4.57.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.05. The business had revenue of $13.01 million during the quarter, compared to the consensus estimate of $8.84 million. As a group, sell-side analysts expect that Stemline Therapeutics Inc will post -1.98 EPS for the current year.

In related news, COO Kenneth Hoberman sold 9,107 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $15.49, for a total value of $141,067.43. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ivan Bergstein sold 56,316 shares of the business’s stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $15.08, for a total transaction of $849,245.28. The disclosure for this sale can be found here. Insiders sold 158,370 shares of company stock worth $2,383,666 in the last 90 days. 13.10% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA bought a new stake in Stemline Therapeutics in the first quarter worth $102,000. Knott David M increased its position in Stemline Therapeutics by 1.3% during the first quarter. Knott David M now owns 157,795 shares of the biopharmaceutical company’s stock valued at $2,028,000 after acquiring an additional 2,000 shares during the last quarter. Bank of America Corp DE increased its position in Stemline Therapeutics by 56.8% during the fourth quarter. Bank of America Corp DE now owns 10,669 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 3,866 shares during the last quarter. Legal & General Group Plc increased its position in Stemline Therapeutics by 27.1% during the fourth quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 1,120 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Stemline Therapeutics by 26.5% during the fourth quarter. Bank of New York Mellon Corp now owns 134,756 shares of the biopharmaceutical company’s stock valued at $1,281,000 after acquiring an additional 28,198 shares during the last quarter. Institutional investors own 78.32% of the company’s stock.

Stemline Therapeutics Company Profile (NASDAQ:STML)

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Recommended Story: Quick Ratio

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.